PRTX 007
Alternative Names: PRTX-007Latest Information Update: 25 Mar 2024
Price :
$50 *
At a glance
- Originator Primmune Therapeutics
- Class Antineoplastics; Antivirals; Small molecules
- Mechanism of Action Toll-like receptor 7 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Hepatitis B
- Preclinical Cancer; Respiratory syncytial virus infections
Most Recent Events
- 25 Mar 2024 Primmune Therapeutics plans a preclinical trial and clinical for Lassa fever
- 10 Nov 2023 Updated adverse events, pharmacokinetics and immunogenicity data from a phase I trial in Hepatitis B presented at the American Association for the Study of Liver Diseases Annual Meeting (AASLD-2023)
- 10 May 2023 PRTX 007 is still in preclinical development for Cancer in USA